Skip to main content

Advertisement

Figure 2 | Journal of Translational Medicine

Figure 2

From: Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B

Figure 2

Mass spectrometry and tandem mass spectrometry of peptide with m/z 520.3. A: Mass spectrometry (MS) in m/z range from 500 to 800 including target peptide peak with m/z of 520.3 (520.6272). B: Tandem mass spectrometry (MS/MS) in m/z range from 0 to 1100 including peptide with m/z of 520.3 (520.9580). Four transition spectra with double charge (520.3/176.1; 520.3/353.7; 520.3/459.8; 520.3/503.3) are also marked in the figure.

Back to article page